Last reviewed · How we verify
Drug: Carfilzomib + Dexamethasone
Carfilzomib inhibits the proteasome to trigger cancer cell death, while dexamethasone is a corticosteroid that enhances anti-myeloma effects and reduces inflammation.
Carfilzomib inhibits the proteasome to trigger cancer cell death, while dexamethasone is a corticosteroid that enhances anti-myeloma effects and reduces inflammation. Used for Multiple myeloma (relapsed or refractory), Multiple myeloma (newly diagnosed).
At a glance
| Generic name | Drug: Carfilzomib + Dexamethasone |
|---|---|
| Also known as | Kyprolis |
| Sponsor | Amgen |
| Drug class | Proteasome inhibitor + corticosteroid combination |
| Target | 20S proteasome (carfilzomib); glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Carfilzomib is a selective proteasome inhibitor that binds irreversibly to the 20S proteasome, preventing degradation of pro-apoptotic proteins and inducing apoptosis in multiple myeloma cells. Dexamethasone, a glucocorticoid, potentiates carfilzomib's cytotoxic effects and provides immunomodulatory and anti-inflammatory benefits. The combination is synergistic in overcoming proteasome inhibitor resistance.
Approved indications
- Multiple myeloma (relapsed or refractory)
- Multiple myeloma (newly diagnosed)
Common side effects
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Dyspnea
- Peripheral neuropathy
- Cardiac toxicity (heart failure)
- Infection
- Hyperglycemia
Key clinical trials
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1, PHASE2)
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (PHASE2)
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (PHASE1)
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) (PHASE3)
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (PHASE3)
- Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial (PHASE1, PHASE2)
- A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (PHASE2)
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: Carfilzomib + Dexamethasone CI brief — competitive landscape report
- Drug: Carfilzomib + Dexamethasone updates RSS · CI watch RSS
- Amgen portfolio CI